Medivation, Inc. (MDVN)

81.44
NASDAQ
Prev Close 81.44
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
3 Biotech Bounce Trades

3 Biotech Bounce Trades

Chart setups in Celgene, Medivation and AMAG Pharmaceuticals.

Medivation (MDVN) Weak On High Volume Today

Medivation (MDVN) Weak On High Volume Today

Trade-Ideas LLC identified Medivation (MDVN) as a weak on high relative volume candidate

Medivation (MDVN): Today's Weak On High Volume Stock

Medivation (MDVN): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Medivation (MDVN) as a weak on high relative volume candidate

Medivation (MDVN) Reaches New Lifetime High Today

Medivation (MDVN) Reaches New Lifetime High Today

Trade-Ideas LLC identified Medivation (MDVN) as a new lifetime high candidate

The Next Chapter in Dendreon's Troubled History: Chapter 11 Bankruptcy

The Next Chapter in Dendreon's Troubled History: Chapter 11 Bankruptcy

A Dendreon agreement calls for a financial restructuring of the company in which the bondholders will receive equity for the debt owed, potentially wiping out current equity shareholders.

Stick With the Price Action

It's the only way to deal with this market.

3 Drugs Stocks Pushing The Industry Higher

3 Drugs Stocks Pushing The Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline

Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline

The diversification away from Xtandi has only just begun.

Despite Stock Market Rally Many Opportunities Still Exist

Despite Stock Market Rally Many Opportunities Still Exist

The trading panel take a look at buying opportunities in the airline and energy industries.

Mid-cap stocks and the Goldilocks economy

Mid-cap stocks and the Goldilocks economy

Mid-cap stocks had better immunity to recent market volatility than smaller companies.

5 Big-Volume Stocks to Trade for Big Breakouts

5 Big-Volume Stocks to Trade for Big Breakouts

These stocks rising on unusual volume are within range of triggering breakout trades.

How Will Medivation (MDVN) Stock Be Affected Today by This Analyst Action?

How Will Medivation (MDVN) Stock Be Affected Today by This Analyst Action?

Shares of Medivation Inc. MDVN are down after the company was downgraded to "neutral" from "buy" at Goldman Sachs.

Medivation (MDVN) Highlighted As Weak On High Volume

Medivation (MDVN) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Medivation (MDVN) as a weak on high relative volume candidate

Analysts' Actions: Goldcorp, Medivation, Morgan Stanley and More

Analysts' Actions: Goldcorp, Medivation, Morgan Stanley and More

Here are today's top research calls.

'Mad Money' Lightning Round: Transocean Is a House of Pain

'Mad Money' Lightning Round: Transocean Is a House of Pain

Cramer says Medivation is for real, he is sticking with Exact Sciences but General Electric is hard to own.

Jim Cramer's 'Mad Money' Recap: An Unsettling Market Decline

Jim Cramer's 'Mad Money' Recap: An Unsettling Market Decline

But as far as Cramer's concerned, it's still business as usual.

New Lifetime High For Medivation (MDVN)

New Lifetime High For Medivation (MDVN)

Trade-Ideas LLC identified Medivation (MDVN) as a new lifetime high candidate

Analysts' Actions: Kohl's, Medivation, Owens-Illinois, Pier 1

Analysts' Actions: Kohl's, Medivation, Owens-Illinois, Pier 1

Here are today's top research calls.

An Indication of Weakness

An Indication of Weakness

Consider going short if you aren't already.

Trade-Ideas: Medivation (MDVN) Is Today's Post-Market Leader Stock

Trade-Ideas: Medivation (MDVN) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Medivation (MDVN) as a post-market leader candidate

Medivation Prostate Cancer Drug Secures Expanded FDA Label

Medivation Prostate Cancer Drug Secures Expanded FDA Label

Language in the new Xtandi label should help Medivation and Astellas widen their market share lead over Johnson & Johnson's competing prostate cancer drug Zytiga.

Medivation (MDVN) Hits New Lifetime High

Medivation (MDVN) Hits New Lifetime High

Trade-Ideas LLC identified Medivation (MDVN) as a new lifetime high candidate

Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte

Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Why Exelixis (EXEL) Stock Plunged to a One-Year Low Today

Why Exelixis (EXEL) Stock Plunged to a One-Year Low Today

Shares of Exelixis (EXEL) plummeted in morning trading Tuesday after the drug developer announced cabozantinib did not prolong survival in subjects with advanced prostate cancer in a Phase III trial.

Ratings Changes Today

Upgrades: AOSL, CREE, DBD, HMIN, ICPT, MDVN, NOR, OLED, PKX, RCPT, RDNT, SCCO, STKL, TIVO, TOWR Downgrades: CIM, HGG, IVC, MASI, MOD, NGL, NICE, PHMD, SRT, TSC, UVV Initiations: LXFT, PTLA, RNA Read on to get TheStreet Quant Ratings' detailed report:

Why Medivation (MDVN) Stock Is Gaining Today

Why Medivation (MDVN) Stock Is Gaining Today

Medivation (MDVN) shares are up almost double digits after having its price target raised by analysts at Brean Capital and Stifel (SF).

Trade-Ideas: Medivation (MDVN) Is Today's Post-Market Leader Stock

Trade-Ideas: Medivation (MDVN) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Medivation (MDVN) as a post-market leader candidate

3 Stocks Underperforming Today In The Health Care Sector

3 Stocks Underperforming Today In The Health Care Sector

TheStreet highlights 3 stocks pushing the health care sector lower today.

'Fast Money' Recap: How Real Is China's 'War of Words'?

'Fast Money' Recap: How Real Is China's 'War of Words'?

The trading panel discussed whether Cisco, EMC or other companies tied to China will be affected.

Trade-Ideas: Medivation (MDVN) Is Today's Post-Market Leader Stock

Trade-Ideas: Medivation (MDVN) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Medivation (MDVN) as a post-market leader candidate